ArticleFrontiers in neurology
The role of microglial Tim-3 in neuroinflammation and functional recovery after spinal cord injury.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3), an immune checkpoint molecule, is highly expressed in microglia and its expression dynamically increases during central nervous system (CNS) development. Although its immunomodulatory functions are well-established, its role in inflammation following spinal cord injury (SCI) remains unclear. This study aimed to elucidate the regulatory role of microglial Tim-3 in the sterile inflammatory response after SCI and to explore its potential as a therapeutic target. Materials and methods: A SCI model was established using C57BL/6 mice. Microglial Tim-3 function was investigated through adeno-associated virus-mediated Tim-3 overexpression and intervention with the Nrf2 agonist Oltipraz. Luxol fast blue (LFB) and Nissl staining were used to assess lesional area and tissue structure. Basso Mouse Scale (BMS) scoring and the sucrose preference test (SPT) were employed to evaluate motor function recovery and depressive-like behavior. Immunofluorescence was performed to analyze glial activation and neurodegeneration. Expression levels of inflammatory factors were measured by enzyme-linked immunosorbent assay (ELISA) and western blot (WB). Key findings: Microglia-specific Tim-3 overexpression promoted microglial proliferation and activation, inducing upregulation of iNOS and robust production of pro-inflammatory cytokines. This exacerbated neural tissue damage and motor dysfunction, whereas depressive-like behaviors were not significantly affected. These effects were partially reversed by the Nrf2 agonist. Significance: AAV-mediated microglial Tim-3 overexpression exacerbates neuroinflammation and functional impairment after SCI, potentially through an association with the Nrf2/HMGB1 signaling axis. Targeting microglial Tim-3 may represent a promising therapeutic strategy for SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.